Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Polycythemia Vera

ClinicalTrials.gov lists 274 trials for Polycythemia Vera or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 13.

MeSH D011087 Neoplasms Neoplasm C04 C15 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 48 Phase 1/2 Phase 1/2 26 Phase 2 Phase 2 90 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 32 Phase 4 Phase 4 3 Not applicable Not applicable 24 Observational Observational 45 Phase 1 Phase 1 48 Phase 1/2 Phase 1/2 26 Phase 2 Phase 2 90 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 32 Phase 4 Phase 4 3 Not applicable Not applicable 24 Observational Observational 45

Trials per phase (log scale)

2 more sections with rows

274 of the 274 trials are tagged with Polycythemia Vera itself; the rest are tagged with a narrower condition beneath it.

Get the Polycythemia Vera report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Polycythemia Vera trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 15

1992: 1 trials (Phase 2 1) 1993: 1 trials (Phase 2 1) 1996: 2 trials (Phase 2 2) 1997: 5 trials (Phase 2 1, Phase 1/2 1, Phase 1 3) 1998: 6 trials (Phase 3 1, Phase 2/3 1, Phase 1/2 1, Phase 1 3) 1999: 8 trials (Not applicable 2, Phase 3 2, Phase 2 1, Phase 1 3) 2000: 6 trials (Not applicable 1, Phase 3 2, Phase 2 2, Phase 1 1) 2001: 5 trials (Not applicable 1, Phase 2 3, Phase 1 1) 2002: 10 trials (Not applicable 1, Phase 2 4, Phase 1/2 3, Phase 1 2) 2003: 1 trials (Phase 1 1) 2004: 6 trials (Observational 1, Phase 2 4, Phase 1 1) 2005: 14 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 3) 2006: 9 trials (Observational 1, Not applicable 2, Phase 2 5, Phase 1 1) 2007: 15 trials (Observational 4, Not applicable 2, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2008: 11 trials (Observational 1, Not applicable 1, Phase 3 3, Phase 2 1, Phase 1/2 4, Phase 1 1) 2009: 15 trials (Other 1, Observational 4, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1/2 2, Phase 1 1) 2010: 9 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1/2 2, Phase 1 3) 2011: 7 trials (Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2012: 9 trials (Observational 2, Phase 3 2, Phase 2 3, Phase 1 2) 2013: 9 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 3, Phase 1/2 2) 2014: 11 trials (Observational 2, Phase 3 4, Phase 2 4, Phase 1 1) 2015: 13 trials (Observational 3, Phase 4 1, Phase 3 1, Phase 2 6, Phase 1 2) 2016: 5 trials (Observational 3, Phase 1 2) 2017: 6 trials (Observational 2, Not applicable 1, Phase 2 3) 2018: 4 trials (Observational 1, Not applicable 1, Phase 2 2) 2019: 11 trials (Observational 1, Phase 3 1, Phase 2 4, Phase 1/2 3, Phase 1 2) 2020: 7 trials (Observational 2, Phase 2 2, Phase 1/2 1, Phase 1 2) 2021: 9 trials (Phase 3 1, Phase 2 7, Phase 1 1) 2022: 10 trials (Observational 4, Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 1) 2023: 7 trials (Observational 2, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1) 2024: 14 trials (Observational 4, Not applicable 2, Phase 3 3, Phase 2 2, Phase 1 3) 2025: 10 trials (Observational 5, Not applicable 1, Phase 2 3, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 12
2025 10
2024 14
2023 7
2022 10
2021 9
2020 7
2019 11
2018 4
2017 6

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 13 trials starting in 2026 and about 12 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 29 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 185 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Polycythemia Vera trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 48
Phase 1/2 26
Phase 2 90
Phase 2/3 3
Phase 3 32
Phase 4 3
Not applicable 24
Observational 45
Expanded access 2
Unknown 1

How many Polycythemia Vera trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 9
Recruiting 37
Active, not recruiting 20
Available 1
Completed 147

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Polycythemia Vera trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 13
Novartis Pharmaceuticals 12
Incyte Corporation 6
Italfarmaco 5
AOP Orphan Pharmaceuticals AG 4

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Polycythemia Vera? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 25
Busulfan 19

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 29
Ruxolitinib IR 28
Peripheral blood stem cell transplantation 26
IR Tacrolimus 16
Total Body Irradiation 15

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Polycythemia Vera trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 100 17
1 yr TRM 93 1
Anemia 59 9
Sepsis 50 18
Pyrexia 39 9

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Polycythemia Vera? (125)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera. Pharmacology research & perspectives 2025 Yes
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood 2024 Yes
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. The New England journal of medicine 2024 Yes
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Annals of hematology 2023 Yes
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera. Future oncology (London, England) 2023 Yes

Showing 5 of 125 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (9)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Polycythemia vera Point prevalence 1-5 / 10 000 Italy Not stated Exact
Polycythemia vera Point prevalence 1-5 / 10 000 Europe Not stated Exact
Polycythemia vera Point prevalence 1-5 / 10 000 Europe Not stated Exact
Polycythemia vera Annual incidence 1-9 / 100 000 Europe Not stated Exact
Polycythemia vera Annual incidence 1-9 / 100 000 Europe Not stated Exact

Showing 5 of 9 prevalence observations.

Start your 14-day trial Email me all 9 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Polycythemia vera 729 Exact Orphanet Rare Disease Ontology (ORDO)
Polycythemia vera 729 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages